Parrott 2005.

Methods	Placebo controlled RCT
Participants	Setting: National multicentre (4) study Country: UK First (93%) or second, cadaveric (88%) or living donor kidney transplant Mean age (treatment/control): 45.8/47.9 years Number (treatment/control): 113 randomised, 108 analysed (52/56) Sex (% male) treatment/control: 67/71 Exclusions: Multiorgan transplant; ABO incompatibility; positive T‐cell or B‐cell crossmatch against donor
Interventions	Treatment group Basiliximab: 20 mg days 0 and 4 Control group Placebo Baseline immunosuppression CSA‐ME: 10 mg/kg/d, adjust to achieve trough levels of 200‐300 ng/mL (month 1), 15‐250 ng/mL (2‐12 months) MMF/AZA: initiated in patients experiencing DGF and discontinued once kidney function established Steroids: initiated in patients experiencing DGF and tapered to zero
Outcomes	Mortality Graft loss Acute rejection DGF
Notes	1 year follow‐up
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Computer generated randomization schedule"
Allocation concealment (selection bias)	Low risk	"Study medication was packed sequentially and numbered... and patients were allocated to the next available treatment pack"
Blinding (performance bias and detection bias) Objective outcomes	Unclear risk	Double‐blind, blinding of outcome assessors not stated
Blinding (performance bias and detection bias) Subjective outcomes	Low risk	Double‐blind, blinding of outcome assessors not stated
Incomplete outcome data (attrition bias) All outcomes	High risk	108/113 analysed. Five excluded, 4 with no transplant, 1 with transplant but no drug. Not ITT analysis as stated
Selective reporting (reporting bias)	Low risk	Primary outcomes for this review (death, graft loss and acute rejection) have been reported
Other bias	High risk	Funded by Novartis Pharmaceuticals, 1/5 authors Novartis employee